Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Melanoma 114Carcinoma, Non-Small-Cell Lung 34Neoplasms 26Neoplasm Metastasis 19Prostatic Neoplasms 18Uveal Melanoma 16Carcinoma, Renal Cell 16Lung Neoplasms 14Pancreatic Neoplasms 13Diabetes Mellitus, Insulin-Dependent, 12 12Small Cell Lung Carcinoma 11Colorectal Neoplasms 10Carcinoma, Hepatocellular 9Uterine Cervical Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Breast Neoplasms 8Sarcoma 7Carcinoma, Transitional Cell 7Brain Neoplasms 7Stomach Neoplasms 6Mesothelioma 6Kidney Neoplasms 6Head and Neck Neoplasms 6Advanced Cancer 6Urinary Bladder Neoplasms 5Recurrence 5Ovarian Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma 5Leukemia, Myeloid, Acute 5

Interventions

Iodine-131 11Thyrotropin Alfa 9Sorafenib 8lenvatinib 6Thyroidectomy 6vandetanib 5Sunitinib 5Saline Solution 5pazopanib 4Triiodothyronine 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Vemurafenib 3Thyroxine 3Radiotherapy 3Everolimus 3Dexmedetomidine 3Control Groups 3Cisplatin 3AZD 6244 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3trametinib 2tipifarnib 2romidepsin 2dabrafenib 2belinostat 2Trastuzumab 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Immunohistochemistry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Thyroid Neoplasms × Ipilimumab × Clear all
NCT03246958 2025-06-19

Nivolumab Plus Ipilimumab in Thyroid Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
53 enrolled 19 charts
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡